Cargando…
The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors
The ineffectiveness and failing of chemotherapeutic treatments are often associated with multidrug resistance (MDR). MDR is primarily linked to the overexpression of ATP-binding cassette (ABC) transporter proteins in cancer cells. ABCG2 (ATP-binding cassette subfamily G member 2, also known as the b...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866861/ https://www.ncbi.nlm.nih.gov/pubmed/36678870 http://dx.doi.org/10.3390/pharmaceutics15010241 |
_version_ | 1784876197003395072 |
---|---|
author | Stockmann, Philipp Kuhnert, Lydia Leinung, Wencke Lakoma, Cathleen Scholz, Birte Paskas, Svetlana Mijatović, Sanja Maksimović-Ivanić, Danijela Honscha, Walther Hey-Hawkins, Evamarie |
author_facet | Stockmann, Philipp Kuhnert, Lydia Leinung, Wencke Lakoma, Cathleen Scholz, Birte Paskas, Svetlana Mijatović, Sanja Maksimović-Ivanić, Danijela Honscha, Walther Hey-Hawkins, Evamarie |
author_sort | Stockmann, Philipp |
collection | PubMed |
description | The ineffectiveness and failing of chemotherapeutic treatments are often associated with multidrug resistance (MDR). MDR is primarily linked to the overexpression of ATP-binding cassette (ABC) transporter proteins in cancer cells. ABCG2 (ATP-binding cassette subfamily G member 2, also known as the breast cancer resistance protein (BCRP)) mediates MDR by an increased drug efflux from the cancer cells. Therefore, the inhibition of ABCG2 activity during chemotherapy ought to improve the efficacy of the administered anti-cancer agents by reversing MDR or by enhancing the agents’ pharmacokinetic properties. Significant efforts have been made to develop novel, powerful, selective, and non-toxic inhibitors of BCRP. However, thus far the clinical relevance of BCRP-selective MDR-reversal has been unsuccessful, due to either adverse drug reactions or significant toxicities in vivo. We here report a facile access towards carboranyl quinazoline-based inhibitors of ABCG2. We determined the influence of different methoxy-substitution patterns on the 2-phenylquinazoline scaffold in combination with the beneficial properties of an incorporated inorganic carborane moiety. A series of eight compounds was synthesized and their inhibitory effect on the ABCG2-mediated Hoechst transport was evaluated. Molecular docking studies were performed to better understand the structure-protein interactions of the novel inhibitors, exhibiting putative binding modes within the inner binding site. Further, the most potent, non-toxic compounds were investigated for their potential to reverse ABCG2-mediated mitoxantrone (MXN) resistance. Of these five evaluated compounds, N-(closo-1,7-dicarbadodecaboran(12)-9-yl)-6,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-quinazolin-4-amine (DMQCd) exhibited the strongest inhibitory effect towards ABCG2 in the lower nanomolar ranges. Additionally, DMQCd was able to reverse BCRP-mediated MDR, making it a promising candidate for further research on hybrid inorganic-organic compounds. |
format | Online Article Text |
id | pubmed-9866861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98668612023-01-22 The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors Stockmann, Philipp Kuhnert, Lydia Leinung, Wencke Lakoma, Cathleen Scholz, Birte Paskas, Svetlana Mijatović, Sanja Maksimović-Ivanić, Danijela Honscha, Walther Hey-Hawkins, Evamarie Pharmaceutics Article The ineffectiveness and failing of chemotherapeutic treatments are often associated with multidrug resistance (MDR). MDR is primarily linked to the overexpression of ATP-binding cassette (ABC) transporter proteins in cancer cells. ABCG2 (ATP-binding cassette subfamily G member 2, also known as the breast cancer resistance protein (BCRP)) mediates MDR by an increased drug efflux from the cancer cells. Therefore, the inhibition of ABCG2 activity during chemotherapy ought to improve the efficacy of the administered anti-cancer agents by reversing MDR or by enhancing the agents’ pharmacokinetic properties. Significant efforts have been made to develop novel, powerful, selective, and non-toxic inhibitors of BCRP. However, thus far the clinical relevance of BCRP-selective MDR-reversal has been unsuccessful, due to either adverse drug reactions or significant toxicities in vivo. We here report a facile access towards carboranyl quinazoline-based inhibitors of ABCG2. We determined the influence of different methoxy-substitution patterns on the 2-phenylquinazoline scaffold in combination with the beneficial properties of an incorporated inorganic carborane moiety. A series of eight compounds was synthesized and their inhibitory effect on the ABCG2-mediated Hoechst transport was evaluated. Molecular docking studies were performed to better understand the structure-protein interactions of the novel inhibitors, exhibiting putative binding modes within the inner binding site. Further, the most potent, non-toxic compounds were investigated for their potential to reverse ABCG2-mediated mitoxantrone (MXN) resistance. Of these five evaluated compounds, N-(closo-1,7-dicarbadodecaboran(12)-9-yl)-6,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-quinazolin-4-amine (DMQCd) exhibited the strongest inhibitory effect towards ABCG2 in the lower nanomolar ranges. Additionally, DMQCd was able to reverse BCRP-mediated MDR, making it a promising candidate for further research on hybrid inorganic-organic compounds. MDPI 2023-01-10 /pmc/articles/PMC9866861/ /pubmed/36678870 http://dx.doi.org/10.3390/pharmaceutics15010241 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stockmann, Philipp Kuhnert, Lydia Leinung, Wencke Lakoma, Cathleen Scholz, Birte Paskas, Svetlana Mijatović, Sanja Maksimović-Ivanić, Danijela Honscha, Walther Hey-Hawkins, Evamarie The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors |
title | The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors |
title_full | The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors |
title_fullStr | The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors |
title_full_unstemmed | The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors |
title_short | The More the Better—Investigation of Polymethoxylated N-Carboranyl Quinazolines as Novel Hybrid Breast Cancer Resistance Protein Inhibitors |
title_sort | more the better—investigation of polymethoxylated n-carboranyl quinazolines as novel hybrid breast cancer resistance protein inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866861/ https://www.ncbi.nlm.nih.gov/pubmed/36678870 http://dx.doi.org/10.3390/pharmaceutics15010241 |
work_keys_str_mv | AT stockmannphilipp themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT kuhnertlydia themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT leinungwencke themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT lakomacathleen themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT scholzbirte themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT paskassvetlana themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT mijatovicsanja themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT maksimovicivanicdanijela themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT honschawalther themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT heyhawkinsevamarie themorethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT stockmannphilipp morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT kuhnertlydia morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT leinungwencke morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT lakomacathleen morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT scholzbirte morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT paskassvetlana morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT mijatovicsanja morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT maksimovicivanicdanijela morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT honschawalther morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors AT heyhawkinsevamarie morethebetterinvestigationofpolymethoxylatedncarboranylquinazolinesasnovelhybridbreastcancerresistanceproteininhibitors |